VRTX - Vertex Pharmaceuticals Incorporated

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
178.560
-6.920 (-3.73%)
As of 9:53AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close185.480
Open184.290
Bid176.730 x 900
Ask176.850 x 800
Day's Range176.710 - 184.290
52 Week Range136.500 - 194.920
Volume409,374
Avg. Volume1,134,870
Market Cap45.633B
Beta (3Y Monthly)1.84
PE Ratio (TTM)110.70
EPS (TTM)1.613
Earnings DateOct 24, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est198.27
Trade prices are not sourced from all markets
  • Vertex Pharmaceuticals (VRTX) Q3 Earnings Preview: What's Shaping Up?
    Zacks23 hours ago

    Vertex Pharmaceuticals (VRTX) Q3 Earnings Preview: What's Shaping Up?

    Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • CELG vs. VRTX: Which Stock Should Value Investors Buy Now?
    Zacksyesterday

    CELG vs. VRTX: Which Stock Should Value Investors Buy Now?

    CELG vs. VRTX: Which Stock Is the Better Value Option?

  • Business Wire2 days ago

    Vertex to Announce Third Quarter 2018 Financial Results on October 24

    Vertex Pharmaceuticals Incorporated (VRTX) will report its third quarter 2018 financial results on Wednesday, October 24, 2018 after the financial markets close. An archived webcast will be available on the company's website. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases.

  • Baystreet2 days ago

    Stocks in play: Kinaxis Inc.

    Announced Vertex Pharmaceuticals Incorporated, a global biotechnology company headquartered in Boston, ...

  • A Look at Vertex Pharmaceuticals’ Operational Performance
    Market Realist6 days ago

    A Look at Vertex Pharmaceuticals’ Operational Performance

    How Is Vertex Pharmaceuticals Positioned in October? Vertex Pharmaceuticals’ (VRTX) cost of sales was $104.38 million in the second quarter of 2018 compared to $71.2 million in the second quarter of 2017. It incurred selling, general, and administrative expenses of $137.3 million in the second quarter of 2018 compared to $127.25 million in the second quarter of 2017.

  • What Vertex Pharmaceuticals’ Valuation Trend Indicates
    Market Realist6 days ago

    What Vertex Pharmaceuticals’ Valuation Trend Indicates

    In October, there are 24 analysts covering Vertex Pharmaceuticals (VRTX) stock. Twenty of them have given the stock a “buy” or higher rating, and four have given it a “hold.” The mean rating for the stock is 1.83 with a target price of $198.27, implying an upside potential of 12.9% over Vertex Pharmaceuticals’ closing price of $175.66 on October 11.

  • How Is Vertex Pharmaceuticals Positioned in October?
    Market Realist6 days ago

    How Is Vertex Pharmaceuticals Positioned in October?

    Vertex Pharmaceuticals (VRTX) is focused on developing and bringing to market therapies that treat cystic fibrosis. Vertex Pharmaceuticals has key collaboration agreements with CRISPR Therapeutics (CRSP) to develop treatments for underlying genetic causes of human diseases by using CRISPR-Cas9 technology. It also uses Moderna Therapeutics to develop mRNA (messenger ribonucleic acid) therapeutics for cystic fibrosis, BioAxone to evaluate VX-210 as a treatment for spinal cord injuries, and Parion Sciences to develop epithelial sodium channel inhibitors to treat pulmonary diseases.

  • Why CRISPR Therapeutics Stock Is Heading Higher Today
    Motley Fool7 days ago

    Why CRISPR Therapeutics Stock Is Heading Higher Today

    CRISPR Therapeutics' stock is jumping in response to a positive regulatory development for its lead therapy.

  • CNBC7 days ago

    Stocks making the biggest move premarket: DAL, WBA, SQ, FLR, AAPL & more

    These are the stocks posting the largest moves before the bell.

  • After-hours buzz: SQ, FLR & more
    CNBC8 days ago

    After-hours buzz: SQ, FLR & more

    See which stocks are posting big moves after the bell on Wednesday.

  • CNBC8 days ago

    After-hours buzz: SQ, FLR & more

    Check out the companies making headlines after the bell: Square SQ stock tumbled 8 percent in after-hours trading following news that CFO Sarah Friar is stepping down . Friar will stay at the company until December before departing to become CEO of Nextdoor, a localized social network for neighborhoods.

  • GlobeNewswire8 days ago

    CRISPR Therapeutics and Vertex Announce FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell Disease

    In addition to the acceptance of the IND announced today, CRISPR and Vertex previously announced that they had obtained approvals of Clinical Trial Applications for CTX001 in multiple countries outside the U.S. for both β-thalassemia and SCD. The companies remain on track to initiate a Phase 1/2 clinical study in SCD by the end of 2018 and are currently enrolling patients with transfusion dependent β-thalassemia in a Phase 1/2 trial in β-thalassemia in Europe. The elevation of HbF by CTX001 has the potential to alleviate transfusion-requirements for β-thalassemia patients and painful and debilitating sickle crises for sickle cell patients.

  • Why the Earnings Surprise Streak Could Continue for Vertex (VRTX)
    Zacks8 days ago

    Why the Earnings Surprise Streak Could Continue for Vertex (VRTX)

    Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

  • 3 Biotech Stocks With Major Incoming Catalysts
    Motley Fool9 days ago

    3 Biotech Stocks With Major Incoming Catalysts

    These three biotechs will soon present clinical trial results that could send their share prices screaming in one direction or the other.

  • Analysts Are Mostly Positive on Neurocrine Biosciences
    Market Realist9 days ago

    Analysts Are Mostly Positive on Neurocrine Biosciences

    Neurocrine Biosciences (NBIX) develops and commercializes therapies for neurology and endocrine disorders. Neurocrine Biosciences’ Ingrezza became the first FDA-approved drug to be approved for the treatment of individuals with tardive dyskinesia. Neurocrine Biosciences’ Ingrezza competes with Teva Pharmaceutical’s (TEVA) Austedo in the tardive dyskinesia drugs market.

  • Ionis Pharmaceuticals’ Revenue Growth Rate
    Market Realist15 days ago

    Ionis Pharmaceuticals’ Revenue Growth Rate

    Ionis Pharmaceuticals (IONS), a leading biopharmaceutical company, has developed a variety of drugs for the treatment of life-threatening diseases through its broadly applicable drug discovery platform. Ionis reported earnings per share of -$0.29 on revenues of $117.7 million during the second quarter, reporting year-over-year growth of 5.0% during the quarter. The chart below compares the company’s revenues since the first quarter of 2017.

  • Business Wire17 days ago

    Vertex Announces Access Contract in Denmark for Current and Future Cystic Fibrosis Medicines

    Vertex Pharmaceuticals (Europe) Limited today announced it has entered into an innovative access contract with the Danish pharmaceutical and procurement organization, Amgros. Effective from today, this first-of-its-kind contract includes current and future CFTR modulator medicines, and means eligible Danish cystic fibrosis (CF) patients will have access to all current medicines as well as future medicines after regulatory approval.

  • How Vertex Pharmaceuticals Is Positioned Financially
    Market Realist20 days ago

    How Vertex Pharmaceuticals Is Positioned Financially

    In the first half of this year, Vertex Pharmaceuticals’ (VRTX) revenue grew ~40% YoY (year-over-year) to $1.4 billion from $994.6 million. Kalydeco, Orkambi, and Symdeko saw revenue of $253.0 million, $311.0 million, and $186.0 million, respectively, in Q2 2018, compared with $250.0 million, $354.0 million, and $34.0 million, respectively, in Q1 2018. Vertex’s revenue growth could boost the First Trust NYSE Arca Biotechnology Index ETF (FBT), of which Vertex comprises ~3.33%.

  • Vertex Pharmaceuticals Strengthens in the Cystic Fibrosis Space
    Market Realist20 days ago

    Vertex Pharmaceuticals Strengthens in the Cystic Fibrosis Space

    Vertex Pharmaceuticals (VRTX) develops medicines for life-threatening diseases and is presently focused on developing drugs for cystic fibrosis and sickle-cell disease, partnering with CRISPR Therapeutics (CRSP) for the latter. Vertex’s Orkambi, Kalydeco, and Symdeko are top drugs in the cystic fibrosis market. Vertex stock’s 52-week low is $136.50, which it reached on December 7, 2017.

  • Better Buy: Vertex Pharmaceuticals Incorporated vs. Galapagos NV
    Motley Fool20 days ago

    Better Buy: Vertex Pharmaceuticals Incorporated vs. Galapagos NV

    Which stock wins in a battle between these two biotechs?

  • Investor's Business Daily22 days ago

    Here's Why The Stock Market Sold Off After The Fed Meeting

    Stocks gave up all their gains and closed well in the red Wednesday, after the Federal Reserve hiked interest rates by a quarter-point, as widely expected.

  • Investor's Business Daily22 days ago

    Stock News Today: Biotechs Help Nasdaq 100 To Day Of Outperformance

    In stock news today, strong showings from biotech stocks Alexion and Incyte lifted the Nasdaq 100 to a gain of nearly 1% in afternoon trading.

  • Is CRISPR Therapeutics AG a Buy?
    Motley Foollast month

    Is CRISPR Therapeutics AG a Buy?

    On one hand, there's the promise of a groundbreaking technology. On the other hand, huge risk. Which hand wins?

  • 3 Top Healthcare Stocks to Buy in September
    Motley Foollast month

    3 Top Healthcare Stocks to Buy in September

    Hint: Think heart pumps, lab services, and cystic fibrosis drugs.

  • Business Wirelast month

    Vertex to Present at the Morgan Stanley Healthcare Conference on September 14

    Vertex Pharmaceuticals Incorporated (VRTX) today announced that management will present at the Morgan Stanley Healthcare Conference on Friday, September 14, 2018 at 12:15 p.m. ET. The audio portion of management’s remarks will be available live through Vertex’s website, www.vrtx.com in the “Investors” section under the “News and Events” page. A replay of the conference webcast will be archived on the company’s website.